WALTHAM, Mass.--(BUSINESS WIRE)--
NeuroMetrix,
Inc. (the "Company") (Nasdaq: NURO), an innovative health care
company that develops wearable medical technology and point-of-care
tests to help patients and physicians manage chronic pain, nerve
diseases, and sleep disorders, today said it plans to issue its 2014
third quarter financial results before the opening of the market on
October 28, 2014. The Company will host a conference call at 8:00 a.m.,
Eastern Time on October 28, 2014 to discuss its financial results as
well as business developments affecting the Company.
The conference call may be accessed in the United States by dialing
800-299-8538 and using the confirmation code 96119195. Internationally,
the conference call may be accessed by dialing 617-786-2902 and using
the same confirmation code. The earnings press release and accompanying
condensed financial statements will be accessible from the Company's
website at www.NeuroMetrix.com
under the "Investor Relations" tab.
A replay of the conference call will be available starting two hours
after the call by dialing 888-286-8010, domestically and 617-801-6888,
internationally. The confirmation code to access the replay is 97270364.
The replay will be available for one week after the conference call.
About NeuroMetrix
NeuroMetrix is an innovative health-care company that develops wearable
medical technology and point-of-care tests that help patients and
physicians better manage chronic pain, nerve diseases, and sleep
disorders. The Company has a major focus on diabetic neuropathies which
affect over 50% of people with diabetes. If left untreated, diabetic
neuropathies trigger foot ulcers that may require amputation and cause
disabling chronic pain. The annual cost of diabetic neuropathies has
been estimated at $14 billion in the United States. The Company markets
the SENSUS® device for treating chronic pain, focusing on
physicians managing patients with neuropathic pain such as painful
diabetic neuropathy. The Company also markets the DPNCheck®,
which is a rapid, accurate, and quantitative point-of-care test for
peripheral neuropathies such as diabetic neuropathy. This product is
used to detect neuropathies at an early stage and to guide treatment.
For more information, please visit http://www.NeuroMetrix.com.
NeuroMetrix, Inc.
Thomas T. Higgins, 781-314-2761
SVP and
Chief Financial Officer
neurometrix.ir@neurometrix.com
Source: NeuroMetrix, Inc.
News Provided by Acquire Media
